ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

People

FDA Accuses Cetero Of Falsifying Data

by Michael McCoy
August 1, 2011 | APPEARED IN VOLUME 89, ISSUE 31

FDA has sent a letter to Cetero Research informing the firm of “objectionable conditions” observed at its Houston bioanalytical facility during a May 2010 inspection. FDA alleges that company chemists falsified dates and times in laboratory records and manipulated equilibrium samples to meet predetermined acceptance criteria. The agency has concluded that data generated at the facility from April 2005 to June 2010, including data customers relied on for new drug applications, are unreliable. Cetero says it informed FDA of the problem after uncovering it two years ago and doesn’t understand why the agency sent the letter.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment